Research across Cirrhosis
Related studies from across the Cirrhosis family.
9 trials tracked for Compensated cirrhosis: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 278 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several multi-drug regimens demonstrated high rates of sustained virologic response (SVR12) in clinical trials. Ombitasvir/Paritaprevir/Ritonavir achieved SVR12 rates of 94.1% 2 and 100% 3, with no instances of on-treatment failure or post-treatment relapse reported in these cohorts.
Combination therapies including ABT-493/ABT-530 4 and ABT-450/r/ABT-267, ABT-333 6 also showed high efficacy. Specifically, the ABT-493/ABT-530 regimen achieved a 99.3% SVR12 rate 4, while the ABT-450/r/ABT-267, ABT-333 regimens reached SVR12 rates of 91.8% and 96.5%, respectively 6.
In a study evaluating Obeticholic acid (10 mg), the number of participants showing improvement in fibrosis by at least one stage without worsening of NASH was 31, 33, and 37 across groups, which did not reach statistical significance (p=0.6172) 5.
AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Cirrhosis family.